El-Serag, H.B., Siegel, A.B., Davila, J.A., et al. (2006) Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: A population-based study. Journal of Hepatology, 44, 158-166. doi:10.1016/j.jhep.2005.10.002

has been cited by the following article:

• TITLE: Can we achieve complete remission in locally advanced unresectable Hepatocellular Carcinoma (HCC) by using Sorafenib? Case report and review of literature from Qatar

  AUTHORS: Kakil Ibrahim Rasul

  KEYWORDS: Hepatocellular Ca; Sorafenib; Chemoembolization

  JOURNAL NAME: Modern Chemotherapy, Vol.1 No.1, July 23, 2012

  ABSTRACT: Patients with HCC continue to have a dismal prognosis, with 1-year and 3-year survival rates of 36 and 17%, respectively. This is in part related to more than two-thirds of tumors being diagnosed at advanced stages, as well as a substantial portion of patients with early HCC failing to receive potentially curative treatments. Systemic therapy for advanced unresectable HCC limited until the discovery of sorafenib, we are reporting a 53 year patient with unresectable HCC achieved complete remission clinically, radiologically and biochemically with sorafenib which is the first case report.